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Figure  1. Bar code denotes donation identification number 
(upper left), blood group (upper right), collection (or production) 
date and time (middle), product code (lower left), and expiration 
date and time (lower right). The biohazard mark was placed 
correctly on the labels of products that were detected to pose 
infection risks.
Implementation of an ISBT 128-Compatible Medical Record 
System to Facilitate Traceability of Stem Cell Products
Kök Hücre Ürünlerinin İzlenebilirliğini Kolaylaştırmak için ISBT 128 Uyumlu Tıbbi Kayıt 
Sisteminin Uygulanması
Can Boğa1, Erkan Maytalman1, Çiğdem Gereklioğlu2, Süheyl Asma2, Fatih Kandemir1, Pelin Aytan1, Aslı Korur2, Mahmut Yeral1, 
İlknur Kozanoğlu3, Hakan Özdoğu1
1Başkent University Faculty of Medicine, Department of Hematology, Ankara, Turkey
2Başkent University Faculty of Medicine, Department of Family Medicine, Ankara, Turkey
3Başkent University Faculty of Medicine, Department of Physiology, Ankara, Turkey
To the Editor,
The Foundation for the Accreditation of Cellular Therapy and 
the Joint Accreditation Committee-ISCT & EBMT (FACT-JACIE) 
demands the tracking of stem cell products, beginning from 
the harvesting of the product from the patient or donor and 
continuing until the time of use in stem cell transplantation 
centers [1]. Relevant follow-up stages for stem cell product 
bags and vials include harvesting, portioning, transportation, 
acceptance at the cell processing unit, processing, storage, 
recycling, release, acceptance at the clinical unit, infusion, 
and recall at the cellular processing unit [1,2,3,4]. Information 
Standard for Blood and Transplant (ISBT) 128 provides unique 
identification and traceability of stem cell products using an 
international coding system [5]. Although this system is required 
to be implemented in accredited centers, many centers could 
not yet begin using this system. Sufficient data are not available 
in the literature about whether this system has facilitated 
workflow or not. This study was planned in order to investigate 
the feasibility of the ISBT 128 coding system.
This is a single-center, cross-sectional, and prospective study 
conducted at a JACIE-accredited center between January 
2012 and December 2016. Cellular therapy production codes 
beginning with ‘S’ were checked against the International 
Council for Commonality in Blood Banking Automation 
registry and unique identifiers for patient, donor, and stem 
cell products were produced. The class, modifier, and additives 
for the product were defined using the terminology table [6]. 
ISBT-compatible software (Turunç v.0.2, Teknik Media, Adana, 
Turkey) was used as the medical recording system. The function 
and the continuity of the system were evaluated every 15 days. 
Time to reach the data of the stem cell product at a certain 
time between harvesting and infusion/disposal and system 
implementation problems were evaluated. For this purpose, cell 
product characteristics were evaluated at every stage for 20 
randomly selected products.
A total of 2703 records belonging to 467 patients/donors were 
analyzed. The distribution of record numbers according to stages 
of the cellular product’s journey were 712 for cell collection, 
1460 for cell processing, 2 for recall of the product, and 561 for 
disposal of the product. A sample of a final allogeneic label is 
shown in Figure 1. The biohazard mark and a written warning 
regarding infectious agents were placed correctly on the labels 
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of the infection-positive products. The time to reach data of 
cell content, portion number, storage location of bags, and 
storage location of vials were 6.1±1.1 s, 5.3±1 s, 6.4±0.9 s, and 
6.4±0.9 s, respectively. No deviation from quarantine procedure 
was identified. Only three label production errors were detected 
(0.097%). No torn labels were produced.
The coding system was seen to facilitate workflow by enabling 
communication between transplant units. Labels that were 
structured in accordance with ISBT 128 could be produced at 
appropriate stages [7,8]. Almost no mix-up error being found in 
our study is a striking result to ensure the safety and reliability 
of the system.
The ISBT 128 system was found to be effective for traceability 
of stem cell products during their journey from harvesting 
to infusion/disposal and it facilitates the workflow in clinical 
practice in transplant and cellular therapy centers.
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